HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C&D’s Naturals Could Help Retain Orajel Customers After Benzocaine Warning

This article was originally published in The Tan Sheet

Executive Summary

Church & Dwight’s Baby Orajel Naturals could fill a potential void in the teething relief market created by FDA’s recent warning children under 2 years should not use the painkiller benzocaine.

You may also be interested in...



FDA Warns Of Deadly Benzocaine Risks, Label Changes Might Be On The Way

Concern that products with the painkiller benzocaine are linked to rare but serious and potentially fatal adverse events prompted an FDA consumer warning and could lead to label and package changes.

Church & Dwight Counts On Line Extensions To Drive 2011 Growth

Church & Dwight looks to line extensions for brands including First Response pregnancy tests and Trojan condoms to help offset possible losses in the oral care segment caused by competitors' pricing war.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel